Notícias

The end of an earnings season can be a great time to discover new stocks and assess how companies are handling the current business environment. Let’s take a look at how UnitedHealth (NYSE:UNH) and the rest of the health insurance providers stocks fared in Q2.

UnitedHealth (UNH) has turned its profits around. Operating earnings rose 55% in the second quarter of 2026, and management raised its full-year adjusted earnings guide to $19.50 to $20 a share. Revenue, though, has nearly stopped growing. So the rest of the recovery rests on something the company only partly controls: the medical bills of the people it insures.

UnitedHealth (UNH) has been facing investor questions surrounding the upcoming release of Medicare A

TPG just bought into the exact Optum clinics that derailed UnitedHealth's profits, and management is hours away from reaffirming guidance that could either validate the deal or reopen a wound investors hoped was healing.

In recent months, UnitedHealth Group has reported better-than-expected earnings, raised its full-year adjusted EPS outlook, tightened medical cost trends, and moved to remove prior authorization requirements for a wide range of services while accelerating payments to rural hospitals. These steps suggest UnitedHealth Group is reshaping how it manages care delivery and insurer‑provider relationships, potentially reducing bureaucracy and improving member and clinician experience across its vast...

CNC's Marketplace recovery is boosting profitability as better pricing, medical cost trends and risk dynamics reshape its earnings outlook.

HUM's Star Ratings recovery is set to show early progress, but October's CMS release will test its MA turnaround and path to a 2028 margin target.

Estee Lauder Companies (NYSE:EL) said fiscal 2026 marked a return to growth and a substantial improvement in profitability as the prestige beauty company advanced its Beauty Reimagined strategy and Profit Recovery and Growth Plan. For the full fiscal year, reported sales rose 5% and organic sales i

CVS delivers strong Q2 growth and raises 2026 targets, but Caremark pressures and medical costs are likely to shape its next move.

CVS Health enters the second half of 2026 with stronger earnings and Aetna gains, but medical costs and Caremark risks cloud the recovery.

CVS Health is rebuilding momentum as Aetna drives stronger profits and higher 2026 guidance, but medical costs and PBM changes could test the recovery.

UnitedHealth's lower medical costs are fueling an earnings recovery, but rising commercial costs and 2027 pricing decisions could test its durability.

MD posts a Q2 earnings beat as stronger cash collections and a favorable payor mix lift results despite lower volumes.

CVS Health (NYSE:CVS) reported second-quarter results that exceeded its expectations, citing earnings growth across all operating segments and raising its full-year outlook for adjusted earnings per share and operating cash flow. Chair and Chief Executive Officer David Joyner said the company gener

(Bloomberg) -- CVS Health Corp. shares fell after the company gave preliminary 2027 profit guidance that disappointed investors and warned of challenges in its pharmacy benefit manager next year, overshadowing a better-than-expected second quarter report.Most Read from BloombergTrump Says Iran Talks Going Well as Hopes Rise for Hormuz DealSpaceX’s AI Splurge Puts Damper on Debut Earnings After IPOChina’s AI Blitz Creates ‘Death Zone’ for Rival US Model MakersTaco Bell Met With Michigan on Parasi

CVS Health earnings surged past tepid forecasts after reporting its health benefit costs fell as a share of premiums. The pharmacy chain hiked its full-year outlook by a bit less than the Q2 beat. Analysts say that management's prudence in trying to grow its health benefits business let the company avoid the worst fallout from surprisingly strong medical care utilization.

CVS heads into Q2 earnings with estimates pointing to revenue and EPS growth as Aetna initiatives and key business segments support results.

Guardant Health (NASDAQ:GH) reported second-quarter 2026 revenue of $335 million, up 44% from a year earlier, as growth accelerated across its oncology, biopharma and data, and screening businesses. The company also raised its full-year revenue outlook, citing demand for its Guardant360 and Shield o

TDOC tops adjusted earnings estimates despite a revenue miss, as Integrated Care and international growth help cushion BetterHelp weakness and a lower 2026 outlook.

Ensign Group beats Q2 earnings and raises its 2026 outlook as higher occupancy, patient days and acquired facilities drive revenue growth.

Humana (NYSE:HUM) said its 2026 performance is tracking in line with expectations, with management emphasizing planned Medicare Advantage margin expansion in 2027, progress in its Stars program and continued operating-cost reductions as key components of its path toward a sustainable pretax margin o

ENI (NYSE:E) reported sharply higher second-quarter and first-half results, citing upstream production growth, favorable market conditions and stronger contributions from its gas, low-carbon and refining-related businesses. Chief Executive Officer Claudio Descalzi said second-quarter pro forma EBIT

HUM's Q2 earnings top estimates as medical membership growth, premium gains and CenterWell strength lift results despite higher costs.

Humana’s shares dipped in morning trading after its results compared unfavorably with other insurers’ performance this quarter The Medicare-focused insurer modestly beat analysts’ profit projections, offered reassurance on medical cost trends and left guidance unchanged on an adjusted basis.

ACHC beats Q2 earnings and revenue estimates as admissions rise and residential treatment grow, prompting higher 2026 guidance despite profit pressure.

MMM, TRV and UNH posted strong Q2 results, with higher guidance, investment strength and growth drivers supporting their 2026 outlooks.

Humana reports earnings Wednesday after its stock surged this year on improving confidence in Medicare Advantage insurers. Investors will be watching medical costs and the company’s outlook.

CNC's Q2 earnings and revenues top estimates as stronger premium and service revenues drive results despite lower membership and higher medical costs.

UHS tops Q2 earnings and revenue estimates as Acute Care and Behavioral Health growth lifts results, even as higher costs weigh on operations.

THC raised its 2026 outlook after Q2 earnings and revenues beat expectations, driven by strong same-facility growth and disciplined expense management.